Home › Funds › NEXTBio Capital Management LP › PTGX
NEXTBio Capital Management LP position in PTGX
PROTAGONIST THERAPEUTICS INC · Health Care
NEXTBio Capital Management LP reported holding 219,333 shares of PTGX (PROTAGONIST THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$30.9M, representing 13.45% of its reported portfolio and ranking #1 among its reported holdings. NEXTBio Capital Management LP has disclosed PTGX holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How NEXTBio Capital Management LP's PTGX position evolved
NEXTBio Capital Management LP first disclosed a stake in PTGX in Q4 2025 at 229,619 shares (US$20.1M). The position peaked in Q3 2026 at 219,333 shares, worth US$30.9M. Across 4 filings, NEXTBio Capital Management LP increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 219,333 shares valued at US$30.9M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 229.62K | $20.05M | New |
| Q1 2026 | 229.62K | $24.20M | Hold |
| Q2 2026 | 219.33K | $26.89M | Reduce |
| Q3 2026 | 219.33K | $30.90M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About PTGX and 13F data
PTGX (PROTAGONIST THERAPEUTICS INC) is a Health Care company. 50 other funds we track also report a position in PTGX — the largest reported positions include Farallon Capital Management (US$778.2M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$778.2M), RTW INVESTMENTS, LP (US$620.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PTGX
- Farallon Capital Management 6.35M sh · $778.25M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 6.35M sh · $778.25M · Q2 2026
- RTW INVESTMENTS, LP 5.06M sh · $620.40M · Q2 2026
- JOHNSON & JOHNSON 2.45M sh · $345.07M · Q3 2026
- Woodline Partners LP 1.41M sh · $173.35M · Q2 2026
- PERCEPTIVE ADVISORS LLC 981.88K sh · $120.36M · Q2 2026
- ADAR1 Capital Management, LLC 960.86K sh · $117.78M · Q2 2026
- Hood River Capital Management LLC 882.74K sh · $108.21M · Q2 2026
- 683 Capital Management, LLC 290.00K sh · $35.55M · Q2 2026
- Eagle Health Investments LP 248.32K sh · $30.44M · Q2 2026
More on NEXTBio Capital Management LP
FAQ
How long has NEXTBio Capital Management LP held PTGX?
NEXTBio Capital Management LP has disclosed PTGX holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is NEXTBio Capital Management LP's current position in PTGX?
As of Q3 2026, NEXTBio Capital Management LP holds 219.33K shares of PTGX (PROTAGONIST THERAPEUTICS INC), valued at $30.90M, representing 13.45% of its reported portfolio and ranking #1.
Has NEXTBio Capital Management LP been buying or selling PTGX?
In the latest 13F filing (Q3 2026), NEXTBio Capital Management LP held unchanged its position in PTGX. The position peaked in Q3 2026 at 219.33K shares.
Which other funds hold PTGX?
Other major institutional holders of PTGX include Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., RTW INVESTMENTS, LP, among 50 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.